HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alfin

This article was originally published in The Rose Sheet

Executive Summary

Exceeds $2 mil. mark under equity financing arrangement, allowing the company to receive increased payments under its settlement with Adrien Arpel founder Adrienne Newman. As planned, Alfin will receive one payment of $150,000, with future installments increased to $50,000 per month from $25,000. The litigation, in which Newman alleged breach of contract, was settled for $1 mil. ("The Rose Sheet" May 18, In Brief). Separately, Alfin shareholders recently approved changing the name of the company to Adrien Arpel, Inc.; the company is now traded on the American Stock Exchange under the symbol RPL...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005716

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel